Lykos Therapeutics (formerly MAPS PBC)
Tara Samiy, PsyD, currently serves as an Adherence Rater for MAPS Public Benefit Corporation, engaging in clinical trials of MDMA-assisted therapy since January 2023. Simultaneously, Tara holds the position of Quality Assurance Manager at Alchemy Community Therapy Center, providing training and supervision for clinical documentation for intern therapists within a nonprofit focused on affordable ketamine therapy. Previous experience includes co-founding Big Picture Wellness, offering psychotherapy and consultation, and serving as a clinician at the Prevention and Recovery in Early Psychosis program. Tara's background includes extensive work with diverse populations, emphasizing early intervention and mental health, alongside a decade-long role as a full-time mother gaining insights into child development and attachment theory. Educational credentials include a PsyD in Clinical Psychology from the California Institute of Integral Studies and a B.S. in Psychobiology and French from UCLA.
Lykos Therapeutics (formerly MAPS PBC)
At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com.